Trial record 1 of 2 for:    16635582 [PUBMED-IDS]
Previous Study | Return to List | Next Study

Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00918736
Recruitment Status : Completed
First Posted : June 11, 2009
Results First Posted : June 11, 2009
Last Update Posted : June 17, 2009
National Science Council, Taiwan
Information provided by:
Kaohsiung Veterans General Hospital.

Brief Summary:
The aim of this study was to investigate the efficacy and safety of three weekly intraarticular injections of Hyaluronate (HA) in patients with unilateral ankle Osteoarthritis (OA).

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: sodium hyaluronate Phase 2

Detailed Description:
Viscosupplementation with 3 to 5 weekly hyaluronate injections is a well-established treatment option in knee osteoarthritis. Previous studies reported that five weekly hyaluronate injections were safe and effective for the treatment of ankle osteoarthritis. However, the effect of three weekly injections has rarely been investigated. Besides, no study to date has assessed whether balance function would change after HA injections in patients with ankle OA. The purpose of this study was to evaluate the efficacy and safety of three weekly injections of sodium hyaluronate (Hyalgan) in patients with unilateral ankle osteoarthritis. Pain, physical function and balance will be assessed as parameters for the effectiveness.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Hyaluronans in the Treatment of Ankle Osteoarthritis
Study Start Date : October 2007
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: hyaluronate injection
All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Drug: sodium hyaluronate
3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.

Primary Outcome Measures :
  1. Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months [ Time Frame: baseline and 6 months ]

Secondary Outcome Measures :
  1. The American Orthopedic Foot and Ankle Society (AOFAS) Ankle/Hindfoot Score [ Time Frame: 6 months ]
  2. Ankle Sagittal Range of Motion [ Time Frame: 6 months ]
  3. Four Clinical Balance Tests [ Time Frame: 6 months ]
  4. the Level of Global Satisfaction Based on a 7-Point Categorical Scale [ Time Frame: 6 months ]
  5. Systemic and Local Adverse Events Recording [ Time Frame: 6 months ]
  6. Rescue Acetaminophen Consumption [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • were 18 years of age or older, reported unilateral ankle pain for at least 6 months and had either reported no significant benefit from conservative treatment (rest, physical therapy, orthoses or pain medications etc.) or were unable to tolerate side effects of medications
  • ankle radiographs taken within 6 months were equivalent to grade 2 or 3 according to the Kellgren-Lawrence grading system (grade 2, definite osteophytes and possible narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone contour)22
  • had a current total AOS score (described below) of > 3 and < 9 (possible range, 0-10)
  • were normally active, not bedridden or confined to a wheelchair, and were able to walk 30 meters without the aid of a walker, crutches or cane
  • were willing to discontinue all nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication (except for rescue medication) for the duration of the study
  • did not receive physical therapy or trial of shoe modifications or orthotics during the study period

Exclusion Criteria:

  • pregnant and lactating women
  • bilateral ankle OA requiring treatment of both ankles
  • chronic ankle instability
  • lower leg trauma other than within the ankle
  • previous orthopedic surgery on the spine, hip or knee
  • presence of active joint infections of foot or ankle
  • previous surgery or arthroscopy on the ankle within 12 months
  • intraarticular steroid or HA injection in the treated ankle within the past 6 months
  • treatment with anticoagulants or immunosuppressives
  • history of rheumatoid arthritis, gout, or any other inflammatory arthropathy
  • history of avian protein allergy
  • presence of other comorbidity (neoplasm, diabetes mellitus, paresis, recent trauma, etc) or poor health status that would interfere with the clinical assessments during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00918736

Department of Physical Medicine and Rehabilitation, Veterans General Hospital, Kaohsiung, Taiwan
Kaohsiung, Taiwan, 813
Sponsors and Collaborators
Kaohsiung Veterans General Hospital.
National Science Council, Taiwan
Principal Investigator: Shu-Fen Sun, MD Veterans General Hospital, Kaohsiung, Taiwan

Responsible Party: Shu-Fen Sun, Kaohsiung Veteran General Hospital Identifier: NCT00918736     History of Changes
Other Study ID Numbers: NSC96-2314-B-075B-006
First Posted: June 11, 2009    Key Record Dates
Results First Posted: June 11, 2009
Last Update Posted: June 17, 2009
Last Verified: June 2009

Keywords provided by Kaohsiung Veterans General Hospital.:
Ankle joint
Hyaluronic acid

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents